APOE and Alzheimer disease: These Phase 1 a/b trials demonstrated that administration of COR388 for 28 days was well tolerated, rapidly absorbed to reach the desired therapeutic concentrations, and reduced the concentration of ApoE fragments in the cerebrospinal fluid, a marker of AD.33